Tag Archives: John R. Seffrin
A Weekly Advocacy Message from Mary Woolley: Help set our nation’s sights high on the Fourth of July
Dear Research Advocate:
Setting our nation’s sights high, rather than watching Rome burn; that’s the advice embedded in a recent op-ed authored by John R. Seffrin, PhD (CEO of the American Cancer Society and Research!America Board Member) and Michael Caligiuri, MD (CEO of the Ohio State University Comprehensive Cancer Center – James Cancer Center Hospital and Solove Research Institute). The authors advocate establishing a national plan, one that puts political differences aside and focuses on combating deadly and tremendously costly disease.
There is a compelling argument to be made that if our nation wants to sustain a balanced budget, it must deploy a disease moonshot. If our nation wants to protect the health and safety of Americans, lead medical progress instead of abandoning it, and fix the debt, health and medical research must be treated as a top national priority. Advocacy is a path that can take us there, if enough of us travel it and we raise our voices loud enough. Join us next week as we continue our national “#curesnotcuts” social media campaign during the 4th of July Congressional Recess. Check here for more information including sample messages. An article in the Portland Tribune and the ongoing regional radio interviews that I’m conducting over the recess are examples of recent media that effectively frame what’s at stake.The goal is to keep research in the news and in the hearts and minds of our nation’s decision-makers. Continue reading →
By John Seffrin and Michael Caligiuri
An excerpt of an op-ed by John R. Seffrin, PhD, CEO of the American Cancer Society Cancer Action Network and Research!America Board member, and Michael A. Caligiuri, MD, director of the Ohio State University Comprehensive Cancer Center and CEO of the James Cancer Hospital and Solove Research Institute published in U.S News & World Report.
Clinical trials are often a patient’s only viable treatment option for surviving cancer – a disease that kills 1,500 people every day in this country. But haphazard federal budget cuts, a consequence of the so-called “sequester” that was initiated in March, threaten to stall or eliminate critical clinical trials nationwide and further threaten important basic laboratory research. For the one in two men and one in three women in America who will hear those three most dreaded words, “You have cancer,” in their lifetime, research provides more than the promise of new treatments and therapies; it offers hope for beating a disease that was once considered a virtual death sentence.
The Ohio State University’s Comprehensive Cancer Center-James Cancer Hospital and Solove Research Institute conducts groundbreaking clinical trials for cancer research. Due to mandated federal budget cuts earlier this year, the National Cancer Institute was already forced to reduce by half the number of participants in clinical trials at OSU. Under sequestration, these trials will likely be completely eliminated this year, affecting patients undergoing treatment for leukemia, lymphoma, breast cancer and a variety of other forms of cancer. Continue reading →